Human Genome Sciences Licenses FivePrime Therapeutics’ Lead Cancer Drug
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 4 (Table of Contents)
Published: 4 Apr-2011
DOI: 10.3833/pdr.v2011.i4.1452 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Human Genome Sciences (HGS) has signed a deal worth up to US$495 M to license FivePrime Therapeutics’ lead pipeline candidate FP-1039, an inhibitor of multiple members of the fibroblast growth factor (FGF) family, in the US, Canada and EU markets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS